Profound Medical Corp. (NASDAQ:PROF)
| Market Cap | 251.09M+2.5% |
| Revenue (ttm) | 19.01M+62.2% |
| Net Income | -32.65M+20.6% |
| EPS | -0.99+32.7% |
| Shares Out | 36.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,954,277 |
| Open | 6.15 |
| Previous Close | 5.68 |
| Day's Range | 6.15 - 6.92 |
| 52-Week Range | 4.80 - 8.95 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 11.00(+59.19%) |
| Earnings Date | Nov 12, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About PROF
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$PROF stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in PROF holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PROF's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PROF Estimated quarterly lobbying spending
Source: U.S. Senate LDA
PROF Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Point in time revenue | $2.30M | 92.55% |
| Service revenue recognized over time | $185.00K | 7.45% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New PROF patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PROF from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PROF
| ETF | Est. Holding Size |
|---|---|
| QQQSInvesco NASDAQ Future Gen 200 ETF | $100.12K |
| DFICDimensional - International Core Equity 2 ETF | $10.74K |
| SPEUState Street SPDR Portfolio Europe ETF | $7.80K |
Estimated from each fund’s disclosed top holdings × AUM
PROF Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PROF’s recent data — informational, not investment advice